New hope for Tough-to-Treat ovarian cancer
NCT ID NCT05636111
Summary
This early-stage trial is testing whether adding a new drug called lurbinectedin to two existing cancer drugs (paclitaxel and bevacizumab) can help control advanced ovarian cancer that has stopped responding to standard platinum-based chemotherapy. The study will enroll 34 women to find the safest dose of this three-drug combination and see if it shows signs of working. Researchers will also closely monitor how the treatment affects the body's immune cells and blood vessels around the tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.